Winston-Salem, NC Apr 28, 2005
Targacept, Inc., a central nervous system-focused biopharmaceutical company, announced today that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate update at the Deutsche Bank 30th Annual Health Care Conference. The presentation is scheduled to occur on Monday, May 2, 2005 at 3:30 PM at the Hyatt Regency Hotel in Baltimore, Maryland.
About Targacept
Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the central nervous system by selectively targeting neuronal nicotinic acetylcholine receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. Targacept's product candidates are designed to selectively target specific NNR subtypes to promote therapeutic effects and limit adverse side effects. Targacept has a marketed product, Inversine(R) (mecamylamine hydrochloride), product candidates in clinical development for cognitive impairment, including Alzheimer's disease and age associated memory impairment, pain and depression, and multiple ongoing preclinical programs.
# # #
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com